PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.82%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-4.34%
G&A reduction while TRAW shows 24.69% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other expenses reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency.
-6.85%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-6.85%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
4.17%
D&A growth while TRAW reduces D&A. John Neff would investigate differences.
16.91%
EBITDA growth below 50% of TRAW's 34.49%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
16.52%
Operating income growth below 50% of TRAW's 34.48%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-5.45%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
16.61%
Pre-tax income growth 50-75% of TRAW's 26.61%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing tax expense. Martin Whitman would check patterns.
16.61%
Net income growth 50-75% of TRAW's 26.66%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
17.14%
EPS change of 17.14% while TRAW is flat. Bruce Berkowitz would examine quality.
17.14%
Diluted EPS change of 17.14% while TRAW is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.